132 related articles for article (PubMed ID: 36308924)
1. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
Fei M; Zhang Q; Zhang L; Zhu X; Du C; Zhang Z
J Pharm Biomed Anal; 2023 Jan; 223():115121. PubMed ID: 36308924
[TBL] [Abstract][Full Text] [Related]
2. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
[TBL] [Abstract][Full Text] [Related]
3. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
4. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
5. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
6. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
7. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure.
Akbas S; Sahin A; Calis S; Oncel H; Capan Y
Pharmazie; 2018 Jul; 73(7):369-374. PubMed ID: 30001769
[TBL] [Abstract][Full Text] [Related]
8. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
Li M; An W; Wang L; Zhang F; Li J; Zhang Y; Li Y; Li H; Ren W; Zhao R; Xia C; Sun L
J Immunol Methods; 2019 Jun; 469():42-46. PubMed ID: 30943379
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W;
BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555
[TBL] [Abstract][Full Text] [Related]
10. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
[TBL] [Abstract][Full Text] [Related]
11. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin
Owen JS; Rackley RJ; Hummel MA; Roepcke S; Huang H; Liu M; Idris TA; Murugesan SMN; Marwah A; Loganathan S; Ranganna G; Barve A; Waller CF; Socinski MA
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):675-689. PubMed ID: 37792130
[TBL] [Abstract][Full Text] [Related]
13. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
[TBL] [Abstract][Full Text] [Related]
15. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
16. Stability and Biosimilarity Assessment of Bevacizumab Monoclonal Antibody; Orthogonal Testing Protocol Coupled With Peptide Mapping-Principal Component Analysis.
Abdelghaffar SH; Hegazy MA; Eltanany BM
J AOAC Int; 2024 Jan; 107(1):177-188. PubMed ID: 37606972
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
[TBL] [Abstract][Full Text] [Related]
18. Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques.
Bana AA; Sajeev N; Halder S; Abbas Masi H; Patel S; Mehta P
Heliyon; 2023 Sep; 9(9):e19478. PubMed ID: 37810070
[TBL] [Abstract][Full Text] [Related]
19. Pre-study and in-study validation of a size-exclusion chromatography method with different detection modes for the analysis of monoclonal antibody aggregates.
Oliva A; Fariña JB; Llabrés M
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1022():206-212. PubMed ID: 27107247
[TBL] [Abstract][Full Text] [Related]
20. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
